JP2016047845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016047845A5 JP2016047845A5 JP2015247222A JP2015247222A JP2016047845A5 JP 2016047845 A5 JP2016047845 A5 JP 2016047845A5 JP 2015247222 A JP2015247222 A JP 2015247222A JP 2015247222 A JP2015247222 A JP 2015247222A JP 2016047845 A5 JP2016047845 A5 JP 2016047845A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- cells
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26020209P | 2009-11-11 | 2009-11-11 | |
| EP09014136.7 | 2009-11-11 | ||
| US61/260,202 | 2009-11-11 | ||
| EP09014136A EP2322555A1 (en) | 2009-11-11 | 2009-11-11 | Antibodies specific for claudin 6 (CLDN6) |
| US36161810P | 2010-07-06 | 2010-07-06 | |
| EP10006956 | 2010-07-06 | ||
| US61/361,618 | 2010-07-06 | ||
| EP10006956.6 | 2010-07-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538239A Division JP5889196B2 (ja) | 2009-11-11 | 2010-11-11 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075017A Division JP6502992B2 (ja) | 2009-11-11 | 2017-04-05 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016047845A JP2016047845A (ja) | 2016-04-07 |
| JP2016047845A5 true JP2016047845A5 (enExample) | 2016-06-23 |
| JP6125604B2 JP6125604B2 (ja) | 2017-05-10 |
Family
ID=43480734
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538239A Active JP5889196B2 (ja) | 2009-11-11 | 2010-11-11 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
| JP2015247222A Active JP6125604B2 (ja) | 2009-11-11 | 2015-12-18 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
| JP2017075017A Active JP6502992B2 (ja) | 2009-11-11 | 2017-04-05 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538239A Active JP5889196B2 (ja) | 2009-11-11 | 2010-11-11 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017075017A Active JP6502992B2 (ja) | 2009-11-11 | 2017-04-05 | クローディン６（ｃｌｄｎ６）に特異的な抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9487584B2 (enExample) |
| EP (4) | EP4461354A3 (enExample) |
| JP (3) | JP5889196B2 (enExample) |
| KR (4) | KR102317098B1 (enExample) |
| CN (4) | CN102741289B (enExample) |
| AU (3) | AU2010318316B2 (enExample) |
| BR (1) | BR112012011143B1 (enExample) |
| CA (2) | CA2775373C (enExample) |
| CY (2) | CY1120300T1 (enExample) |
| DK (2) | DK2499161T3 (enExample) |
| ES (3) | ES2988907T3 (enExample) |
| HR (2) | HRP20171749T1 (enExample) |
| HU (2) | HUE049404T2 (enExample) |
| IL (2) | IL218628B (enExample) |
| LT (2) | LT2499161T (enExample) |
| ME (1) | ME02943B (enExample) |
| MX (3) | MX347150B (enExample) |
| NO (1) | NO2499161T3 (enExample) |
| NZ (2) | NZ716587A (enExample) |
| PL (3) | PL2499161T3 (enExample) |
| PT (2) | PT2499161T (enExample) |
| RS (2) | RS60168B1 (enExample) |
| RU (1) | RU2675997C2 (enExample) |
| SG (2) | SG10202110692WA (enExample) |
| SI (2) | SI3305813T1 (enExample) |
| SM (1) | SMT201700566T1 (enExample) |
| UA (2) | UA128302C2 (enExample) |
| WO (1) | WO2011057788A1 (enExample) |
| ZA (1) | ZA201202418B (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US12492253B1 (en) * | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| ES2963717T3 (es) | 2009-02-20 | 2024-04-01 | Astellas Pharma Inc | Métodos y composiciones para el diagnóstico y tratamiento del cáncer |
| RU2675997C2 (ru) | 2009-11-11 | 2018-12-25 | Ганимед Фармасьютикалз Аг | Антитела, специфичные к клаудину 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| TWI638833B (zh) | 2010-11-30 | 2018-10-21 | 中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| RS58087B1 (sr) * | 2011-05-13 | 2019-02-28 | Ganymed Pharmaceuticals Gmbh | Antitela za lečenje kancera koji eksprimira klaudin 6 |
| ES2703936T3 (es) * | 2011-05-13 | 2019-03-13 | Ganymed Pharmaceuticals Gmbh | Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6 |
| CN103320381B (zh) * | 2012-03-23 | 2015-04-15 | 上海市儿童医院 | 一种多能干细胞表面标志物及其用途 |
| CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| CN105073776B (zh) * | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
| BR122020024124B1 (pt) * | 2012-11-13 | 2024-01-30 | Biontech Ag | Agentes para tratamento de doenças cancerosas expressando claudina |
| EP3738612A1 (en) * | 2013-07-31 | 2020-11-18 | Biontech AG | Diagnosis and therapy of cancer involving cancer stem cells |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| BR112016010169A2 (pt) * | 2013-11-06 | 2017-12-05 | Stemcentrx Inc | anticorpos anticlaudina e métodos de uso |
| TWI652279B (zh) | 2013-11-11 | 2019-03-01 | 中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
| SI3708579T1 (sl) | 2014-04-01 | 2024-09-30 | Biontech Cell & Gene Therapies Gmbh | Klavdin-6 specifični imunoreceptorji in T celični epitopi |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| EP4632120A3 (en) | 2014-11-11 | 2026-01-07 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
| EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | CANCER TREATMENT COMBINATIONS |
| US10882906B2 (en) | 2016-12-07 | 2021-01-05 | Osaka University | Claudin 5 antibody, and medicine containing said antibody |
| KR102667026B1 (ko) | 2017-05-08 | 2024-05-20 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 항 cldn-5 항체, 및 그 항체를 함유하는 의약 |
| WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| SG11202001430SA (en) | 2017-09-29 | 2020-04-29 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| EP3720963A4 (en) | 2017-12-05 | 2021-12-08 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137 |
| EP3735463A4 (en) * | 2018-01-05 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| JP7374499B2 (ja) * | 2018-10-09 | 2023-11-07 | 公立大学法人福島県立医科大学 | 子宮体癌患者の予後予測バイオマーカー |
| MA54955A (fr) * | 2019-02-15 | 2021-12-22 | Integral Molecular Inc | Anticorps anti-claudine 6 et leurs utilisations |
| SG11202109986TA (en) | 2019-03-20 | 2021-10-28 | Univ California | Claudin-6 antibodies and drug conjugates |
| TWI856078B (zh) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途 |
| PH12021552960A1 (en) | 2019-07-10 | 2022-07-25 | Chugai Pharmaceutical Co Ltd | Claudin-6 binding molecules and uses thereof |
| CN111087465B (zh) | 2019-12-24 | 2020-12-08 | 广州医科大学 | 一种针对密蛋白6的抗体偶联药物及应用 |
| JP6971419B2 (ja) | 2020-03-31 | 2021-11-24 | 中外製薬株式会社 | クローディン６を標的とする多重特異性抗原結合分子およびその使用 |
| CA3212530A1 (en) * | 2021-03-05 | 2022-09-09 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-cldn6 antibody and use thereof |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| JPWO2023053282A1 (enExample) | 2021-09-29 | 2023-04-06 | ||
| EP4562046A1 (en) * | 2022-07-29 | 2025-06-04 | Legend Biotech Ireland Limited | Claudin-6 binding moieties and uses thereof |
| KR20250097820A (ko) | 2022-10-31 | 2025-06-30 | 아스텔라스세이야쿠 가부시키가이샤 | Toll양 수용체 7/8 듀얼 아고니스트 화합물을 포함하는 항체 약물 복합체 |
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| CN116064622B (zh) * | 2023-02-13 | 2023-10-13 | 优睿赛思(武汉)生物科技有限公司 | Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用 |
| WO2024235175A1 (zh) * | 2023-05-12 | 2024-11-21 | 智泽童康(广州)生物科技有限公司 | 抗cldn6抗体及其用途 |
| CN121793985A (zh) | 2023-05-25 | 2026-04-03 | 加利福尼亚大学校董会 | 治疗癌症的方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| CN119320451B (zh) * | 2024-08-21 | 2025-05-16 | 百吉生物医药(广州)股份有限公司 | 一种紧密连接蛋白抗体d03及其应用 |
| CN118754987B (zh) * | 2024-08-21 | 2025-02-11 | 广州百吉生物制药有限公司 | 一种紧密连接蛋白抗体h04及其应用 |
| CN119371534B (zh) * | 2024-08-21 | 2025-05-27 | 百吉生物医药(广州)股份有限公司 | 一种紧密连接蛋白抗体e02及其应用 |
| WO2026084392A1 (ko) * | 2024-10-14 | 2026-04-23 | 에이비엘바이오 주식회사 | 항-클라우딘6 항체 및 이의 용도 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
| US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO2000035937A1 (en) | 1998-12-17 | 2000-06-22 | Human Genome Sciences, Inc. | 47 human secreted proteins |
| WO2000012708A2 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
| US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU773028B2 (en) | 1998-11-03 | 2004-05-13 | Adherex Technologies Inc. | Compounds and methods for modulating claudin-mediated functions |
| AU3479700A (en) | 1999-02-22 | 2000-09-14 | Incyte Pharmaceuticals, Inc. | Genes associated with diseases of the colon |
| DK1185648T3 (da) | 1999-06-02 | 2007-07-30 | Genentech Inc | Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst |
| EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
| AU778863B2 (en) * | 1999-07-12 | 2004-12-23 | Genentech Inc. | Blocking immune response to a foreign antigen using an antagonist which binds to CD20 |
| EP1242443A4 (en) | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
| WO2001051513A2 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Ovarian tumor-associated sequences |
| ATE450621T2 (de) | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind |
| AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2412211A1 (en) | 2000-06-23 | 2002-01-03 | Genetech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| AU2001273150A1 (en) | 2000-07-20 | 2002-02-05 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| EP1311530A4 (en) | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| CA2450793A1 (en) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| CA2379661A1 (en) * | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
| CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA2500687A1 (en) | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| JP2006516192A (ja) | 2002-10-18 | 2006-06-29 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2006033664A1 (en) | 2004-03-08 | 2006-03-30 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| ITRM20050297A1 (it) * | 2005-06-08 | 2006-12-09 | Univ Siena | Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi. |
| JP5364870B2 (ja) | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| ES2625798T3 (es) * | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| US8129502B2 (en) * | 2006-11-13 | 2012-03-06 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| JPWO2008114733A1 (ja) | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | 抗Ｃｌａｕｄｉｎ−４抗体 |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2009025759A1 (en) * | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| WO2009028663A1 (ja) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| US9274119B2 (en) * | 2008-01-11 | 2016-03-01 | The University Of Tokyo | Anti-CLDN6 antibody |
| JP2011516580A (ja) | 2008-04-11 | 2011-05-26 | バイオノボ・インコーポレーテッド | トウサイカチｇｌｅｄｉｔｓｉａｓｉｎｅｎｓｉｓｌａｍの抽出物を用いる抗癌方法 |
| WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| DE102009026960A1 (de) | 2008-12-18 | 2010-07-01 | Robert Bosch Gmbh | Verfahren zur Steuerung einer Bremsbetätigung eines Hybridfahrzeugs |
| ES2963717T3 (es) | 2009-02-20 | 2024-04-01 | Astellas Pharma Inc | Métodos y composiciones para el diagnóstico y tratamiento del cáncer |
| EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
| EP2322555A1 (en) | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| RU2675997C2 (ru) | 2009-11-11 | 2018-12-25 | Ганимед Фармасьютикалз Аг | Антитела, специфичные к клаудину 6 (cldn6) |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| RS58087B1 (sr) * | 2011-05-13 | 2019-02-28 | Ganymed Pharmaceuticals Gmbh | Antitela za lečenje kancera koji eksprimira klaudin 6 |
| EP2605017A1 (de) | 2011-12-16 | 2013-06-19 | Protagen AG | Markersequenzen für gynäkologisches Malignom und deren Verwendung |
| AU2013292510A1 (en) | 2012-07-19 | 2015-02-05 | Amgen Inc. | Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof |
| CN105073776B (zh) * | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
| SI3708579T1 (sl) * | 2014-04-01 | 2024-09-30 | Biontech Cell & Gene Therapies Gmbh | Klavdin-6 specifični imunoreceptorji in T celični epitopi |
-
2010
- 2010-11-11 RU RU2012123995A patent/RU2675997C2/ru active
- 2010-11-11 ES ES20151560T patent/ES2988907T3/es active Active
- 2010-11-11 PL PL10778877T patent/PL2499161T3/pl unknown
- 2010-11-11 UA UAA201805468A patent/UA128302C2/uk unknown
- 2010-11-11 PT PT107788770T patent/PT2499161T/pt unknown
- 2010-11-11 ME MEP-2017-261A patent/ME02943B/me unknown
- 2010-11-11 LT LTEP10778877.0T patent/LT2499161T/lt unknown
- 2010-11-11 HU HUE17189247A patent/HUE049404T2/hu unknown
- 2010-11-11 CN CN201080051324.8A patent/CN102741289B/zh active Active
- 2010-11-11 ES ES10778877.0T patent/ES2649389T3/es active Active
- 2010-11-11 US US13/503,461 patent/US9487584B2/en active Active
- 2010-11-11 KR KR1020207017665A patent/KR102317098B1/ko active Active
- 2010-11-11 HR HRP20171749TT patent/HRP20171749T1/hr unknown
- 2010-11-11 MX MX2012005444A patent/MX347150B/es active IP Right Grant
- 2010-11-11 NO NO10778877A patent/NO2499161T3/no unknown
- 2010-11-11 JP JP2012538239A patent/JP5889196B2/ja active Active
- 2010-11-11 SI SI201031999T patent/SI3305813T1/sl unknown
- 2010-11-11 SM SM20170566T patent/SMT201700566T1/it unknown
- 2010-11-11 DK DK10778877.0T patent/DK2499161T3/da active
- 2010-11-11 CN CN202010370074.XA patent/CN111875703B/zh active Active
- 2010-11-11 EP EP24193389.4A patent/EP4461354A3/en active Pending
- 2010-11-11 BR BR112012011143A patent/BR112012011143B1/pt active IP Right Grant
- 2010-11-11 SG SG10202110692WA patent/SG10202110692WA/en unknown
- 2010-11-11 EP EP17189247.4A patent/EP3305813B1/en active Active
- 2010-11-11 KR KR1020197007436A patent/KR102126964B1/ko active Active
- 2010-11-11 MX MX2017004846A patent/MX385874B/es unknown
- 2010-11-11 SI SI201031568T patent/SI2499161T1/sl unknown
- 2010-11-11 SG SG10201500975YA patent/SG10201500975YA/en unknown
- 2010-11-11 CN CN201510347761.9A patent/CN105348389B/zh active Active
- 2010-11-11 LT LTEP17189247.4T patent/LT3305813T/lt unknown
- 2010-11-11 CA CA2775373A patent/CA2775373C/en active Active
- 2010-11-11 KR KR1020127012326A patent/KR101960509B1/ko active Active
- 2010-11-11 CA CA3050655A patent/CA3050655C/en active Active
- 2010-11-11 WO PCT/EP2010/006888 patent/WO2011057788A1/en not_active Ceased
- 2010-11-11 DK DK17189247.4T patent/DK3305813T3/da active
- 2010-11-11 EP EP10778877.0A patent/EP2499161B8/en active Active
- 2010-11-11 UA UAA201207057A patent/UA117799C2/uk unknown
- 2010-11-11 HU HUE10778877A patent/HUE035516T2/en unknown
- 2010-11-11 EP EP20151560.8A patent/EP3689911B1/en active Active
- 2010-11-11 AU AU2010318316A patent/AU2010318316B2/en active Active
- 2010-11-11 RS RS20200427A patent/RS60168B1/sr unknown
- 2010-11-11 PT PT171892474T patent/PT3305813T/pt unknown
- 2010-11-11 NZ NZ716587A patent/NZ716587A/en unknown
- 2010-11-11 KR KR1020217033643A patent/KR20210130250A/ko not_active Ceased
- 2010-11-11 PL PL17189247T patent/PL3305813T3/pl unknown
- 2010-11-11 ES ES17189247T patent/ES2784483T3/es active Active
- 2010-11-11 NZ NZ734307A patent/NZ734307A/en unknown
- 2010-11-11 CN CN201610429065.7A patent/CN106432500B/zh active Active
- 2010-11-11 RS RS20171131A patent/RS56502B1/sr unknown
- 2010-11-11 PL PL20151560.8T patent/PL3689911T3/pl unknown
-
2012
- 2012-03-14 IL IL218628A patent/IL218628B/en active IP Right Grant
- 2012-04-03 ZA ZA2012/02418A patent/ZA201202418B/en unknown
- 2012-05-09 MX MX2020011790A patent/MX2020011790A/es unknown
-
2015
- 2015-12-18 JP JP2015247222A patent/JP6125604B2/ja active Active
-
2016
- 2016-04-11 AU AU2016202235A patent/AU2016202235B2/en active Active
- 2016-04-20 US US15/133,783 patent/US9932401B2/en active Active
- 2016-07-11 IL IL246710A patent/IL246710B/en active IP Right Grant
-
2017
- 2017-04-05 JP JP2017075017A patent/JP6502992B2/ja active Active
- 2017-11-27 CY CY20171101246T patent/CY1120300T1/el unknown
-
2018
- 2018-01-31 US US15/885,454 patent/US10745477B2/en active Active
- 2018-03-07 AU AU2018201640A patent/AU2018201640B2/en active Active
-
2020
- 2020-04-14 HR HRP20200591TT patent/HRP20200591T1/hr unknown
- 2020-04-15 CY CY20201100363T patent/CY1123192T1/el unknown
- 2020-07-07 US US16/922,179 patent/US11858988B2/en active Active
-
2023
- 2023-11-27 US US18/520,242 patent/US20240092896A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012123995A (ru) | Антитела, специфичные к клаудину 6 (cldn6) | |
| KR102503084B1 (ko) | 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도 | |
| KR102952460B1 (ko) | Cd3 항체 및 그의 약제학적 용도 | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| AU2017226510B2 (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| CN102239182B (zh) | Muc1*抗体 | |
| JP2020510422A5 (enExample) | ||
| JP2021508469A5 (enExample) | ||
| RU2019111277A (ru) | Новые моноклональные антитела к белку программируемой смерти 1(pd-1) | |
| JP2020501531A5 (enExample) | ||
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2010532169A5 (enExample) | ||
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| JP2018510636A5 (enExample) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2013545455A5 (enExample) | ||
| JP2014530017A5 (enExample) | ||
| JP2018507188A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| WO2014185704A1 (ko) | Her2에 특이적으로 결합하는 항체 | |
| WO2022171100A1 (zh) | Gpc3人源化抗体及其应用 | |
| WO2022166876A1 (zh) | 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用 | |
| CN104093741B (zh) | 小鼠抗Aggrus单克隆抗体 |